Employers and Biosimilars: Stories from the Real World (Webinar)

Employers are looking to biosimilars for help in controlling the ever-increasing financial burden on employee benefits. Biosimilars are considered “highly similar” to FDA-approved biologic originator drugs, with no clinically meaningful differences in terms of safety, purity and potency. Currently, over 80% of biosimilars run through the medical claims side. Employers need to require that clinical protocols are clearly defined in carrier contracts and mandate the appropriate use of biosimilars for patient efficacy and cost effective outcomes. Biosimilars can reduce pharmacy benefit costs significantly, just as generic drugs have done.

At this webinar, you will learn:

• Employer steps required to implement biosimilars
• Best practices for optimal plan savings
• How to address the challenges in promoting individual access and adoption
• How artificial price increases, rebates and other barriers are used to discourage coverage and what to do about it

Presenters: Alex Jung & Kimberly Dwyer